Form: SC 13G

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions

August 25, 2020

Exhibit 99.1

 

JOINT FILING AGREEMENT

 

The undersigned hereby agree that statements on Schedules 13G and/or 13D and Forms 3, 4 and 5 with respect to the securities of Sutro Biopharma, Inc. and any amendments thereto signed by each of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended. The undersigned hereby further agree that this Joint Filing Agreement may be included as an exhibit to such statements or amendments. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

 

Dated: August 24, 2020

 

    Ridgeback Capital Investments L.P.
     
  By:

Ridgeback Capital Investments Ltd.,

Its General Partner

     
  By: /s/ Bud Holman 
    Name: Bud Holman
    Title: Director

 

    Ridgeback Capital Investments Ltd.
     
  By: /s/ Bud Holman
    Name: Bud Holman
    Title: Director

 

    Ridgeback Capital Management LLC
     
  By: /s/ Bud Holman
    Name: Bud Holman
    Title: Authorized Signatory